Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Specimen Handling 439Magnetic Resonance Spectroscopy 341pembrolizumab 288Biopsy 241Carboplatin 230Cisplatin 193Cyclophosphamide 185Paclitaxel 164Nivolumab 153Gemcitabine 151Bevacizumab 121Radiotherapy 119Dexamethasone 113fludarabine 99Pemetrexed 99Fluorouracil 94durvalumab 90Doxorubicin 90venetoclax 89Docetaxel 89Radiation 88Oxaliplatin 88Rituximab 87atezolizumab 84Leucovorin 79Capecitabine 75Prednisone 74Lenalidomide 69Etoposide 69X-Rays 65

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × methoxyamine × 30 days × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡